Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials

Journal of Neuro-Oncology

Volumn 12, Issue 3, 1992, Pages 219-227

  Curran Jr , Walter J ^a   Scott, Charles B ^b   Horton, John ^c   Nelson, James S ^d   Weinstein, Alan S ^e   Nelson, Diane F ^f   Fischbach, A Jennifer ^e   Chang, Chu H ^g   Rotman, Marvin ^h   Asbell, Sucha O ^a   Powlis, William D ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^e Highland Hosp ^*  (United States)

^f LDS HOSPITAL   (United States)

^g STATE UNIVERSITY OF NEW YORK   (United States)

^h ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

anaplastic astrocytoma; glioma; surgery

Indexed keywords

CARMUSTINE;

ADULT; ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; NEUROSURGERY; RADIOTHERAPY;

ADULT; AGE FACTORS; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; FRONTAL LOBE; HUMAN; MIDDLE AGE; PARIETAL LOBE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TEMPORAL LOBE;

EID: 0026538114     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/BF00172709     Document Type: Article

References (36)

1. National survey of patterns of care for brain-tumor patients
2. Comparison of postoperative radiotherapy and chemotherapy in the multi-disciplinary management of malignant gliomas
3. Hyperfractionation in malignant glioma: Report on a dose searching phase I/II protocol of the Radiation Therapy Oncology Group (RTOG)
4. Misonidazole combined with hyperfractionation in the management of malignant glioma
5. Survival and quality of life after interstitial implantation of removable high-activity Iodine-125 sources for the treatment of patients with recurrent malignant gliomas
6. Misonidazole in radiotherapy of supratentorial malignant brain gliomas in adult patients: A randomized double-blind study
7. Initial analysis of NCOG 6G82-1: Bromodeoxyuridine (BUdR) during irradiation followed by CCNU, procarbazine, and vincristine (PCV) chemotherapy for malignant glioma
8. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma
9. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
10. ‘Eight-drugs-in-one-day’ chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas
11. Needle biopsy, high-dose corticosteroids, and radiotherapy in the treatment of malignant glial tumors
12. Cortical localization and monitoring during cerebral operations
13. Computer-assisted stereotaxic laser resection of intra-axial neoplasms
14. Survival after stereotactic biopsy of malignant gliomas
15. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults
16. Surgical resection of malignant brain tumors: Who benefits?
17. CT prognostic criteria of survival after malignant glioma surgery
18. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients
19. Supratentorial gliomas: Surgical considerations and immediate postoperative results. Gross total resection versus partial resection
20. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas
21. Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications
22. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study
23. Design and analysis of randomized trials required prolonged observation of each patient. II. Analysis and examples
24. Regression models and life tables
25. Nonparametric estimation from incomplete observations
26. Prognostic factors for high-grade malignant glioma: Development of a prognostic index
27. Prognostic factors for patients with brain tumors
28. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas
29. Reoperation for malignant astrocytoma
30. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group report
31. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group
32. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features
33. An analysis of radiation therapy in 178 cases
34. Glioblastoma multiforme. Its treatment and some factors effecting survival
35. Evaluation of CCNU, VM-26 Plus CCNU, and procarbazine in supratentorial brain gliomas: Final evaluation of a randomized study
36. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas